01 December 2009
Expression pattern of HLA class I antigens in renal cell carcinoma and primary cell line cultures: methodological implications for immunotherapy
Libor HanakABCDEF, Ondrej SlabyABCDEF, Ludmila LauerovaBCD, Leos KrenBCD, Rudolf NenutilCD, Jaroslav MichalekAEGMed Sci Monit 2009; 15(12): CR638-643 :: ID: 878282
Abstract
Background
Renal cell carcinomas have developed various strategies to escape immune cell recognition, including down-regulation or loss of classic HLA class I antigens (A, B, C) and aberrant expression of non-classic HLA class I antigens (G, E). In this study both classic and non-classic HLA class I antigens were tested in tumor specimens and established primary cell cultures derived from renal cell carcinoma patients.
Material and Method
HLA class I antigens were evaluated by immunohistochemical staining and the intensity of cytoplasmic staining was measured semiquantitatively. Renal tumor tissue obtained from nephrectomy was used for the explant culture. MTT assay was performed to test the chemoresistance of primary cell line cultures to common cytostatics.
Results
HLA-G and HLA-E were found in 62% and 100% of the analyzed tumor samples, respectively. Markedly higher levels of the non-classic HLA-G and -E antigens compared with the classic HLA-A, -B, and -C antigens were observed. The cells of the control renal tissues were HLA-A, -B, -C, and -E positive and HLA-G negative. Cell line cultures were successfully established in 85% of the renal cell carcinoma specimens. No or minimal changes in classic HLA-A, B, and C antigen staining were observed during cultivation of the primary cell line cultures. No correlation between HLA class I antigen expression and chemoresistance, histopathological stage, or nuclear grade was found.
Conclusions
These findings suggest that primary cell line cultures derived from surgical specimens of renal cell carcinomas are a feasible model for immunotherapy research through their high cultivation potential.
Keywords: Immunotherapy, Histocompatibility Antigens Class I - metabolism, HLA-G Antigens, HLA-C Antigens - metabolism, HLA-B Antigens - metabolism, HLA-A Antigens - metabolism, HLA Antigens - metabolism, Cell Culture Techniques - methods, Carcinoma, Renal Cell - therapy, Kidney Neoplasms - therapy, Tumor Cells, Cultured
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952